[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypersensitivity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypersensitivity":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,84,115,144,177,201],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":4,"leadSponsor":44,"locationsCount":47},"100054447","activation-and-function-of-eosinophils-in-conditions-with-blood-or-tissue-eosinophilia-100054447",false,"NCT00001406","Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia","Eosinophil Activation and Function in Parasitic Infections and Other Conditions With Increased Tissue or Peripheral Blood Eosinophilia in Humans","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Male or female, aged 1-100\n3. Ability of subject (or Legally Authorized Representative (LAR)) to understand and sign a written informed consent document\n\n   Eosinophilic Patients only:\n4. Documented peripheral blood count \\>1500\u002Fmm3, tissue eosinophilia (abnormal accumulation of eosinophils in the skin or other body tissues) or suspected eosinophilic end organ involvement\n5. Primary (non-NIH) physician for routine medical care\n\n   Relatives only:\n6. Extended family member of an eosinophilic participant on this protocol\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Any condition(s) or diagnosis, physical and\u002For psychological, that the investigator feels precludes the patient from participation in the study.\n\n   Relatives only:\n2. Females must not be pregnant","ALL","1 Year","100 Years",{"count":20,"type":21},800,"ESTIMATED","OBSERVATIONAL","This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions. Eosinophil counts often rise in response to allergies, asthma, and parasitic worm infections. They can also go up in uncommon autoimmune conditions and, rarely, in association with tumors. Elevated levels of these cells is called eosinophilia. Usually, eosinophilia causes no apparent symptoms, but in rare cases there may be local swelling and itching, allergic lung problems, heart disease or nerve damage caused by the release of toxic substances in these cells into body tissues.\n\nPatients 1 to 100 years of age with eosinophil counts greater than 750\u002Fml or an abnormal accumulation of eosinophils in the skin or body tissues may be eligible for this study. All participants will have a thorough medical history, physical examination and blood tests. Depending on the person's age and symptoms, other diagnostic tests may be done, including specialized studies of the eye, lungs, skin, bone marrow, nerves or heart. This is not a treatment study, and no experimental treatments will be offered. Patients who require treatment will receive standard medical care.\n\nCertain other procedures may be requested solely for research purposes. All participants will be asked to donate extra blood for laboratory studies investigating how immune cells and other immune substances in the blood act to stimulate a rise in eosinophils. In addition, some participants may undergo one or more of the following:\n\n* Annual Follow-up evaluations - Physical examinations and blood tests to evaluate changes in the patient's condition and eosinophil counts over time.\n* Bone marrow biopsy and aspiration will be recommended during the initial evaluation, and in certain patients at other times when it is important to look directly at the newly developing cells in the bone marrow. For this procedure an area of skin and bone is anesthetized with xylocaine (an anesthetic similar to that used by dentists), and a very sharp needle is used to sample the bone marrow for evaluation. Bone marrow biopsy and aspiration can have side effects of pain and\u002For bleeding into the skin and soft tissues at the site of the procedure. Rarely the area at the biopsy site can become infected, and is treated with antibiotics.\n* Genetic testing: Some of the blood drawn from you as part of this study will be used for genetic tests. Genetic tests can help researchers study how health or illness is passed on to you by your parents or from you to your children. Any genetic information collected or discovered about you or your family will be confidential.\n* Leukapheresis (only patients 18 years and older) to collect large numbers of certain cells - In this procedure, whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm....",[25,26,27,28,29],"Immune System Diseases","Eosinophilia","Helminthiasis","Hypersensitivity","Parasitic Disease",[31,32,33,34,35,36],"Eosinophils","Helminth Parasites","Hypereosinophilia","Allergy","Asthma","Natural History","RECRUITING","2026-06-03",{"date":40,"type":41},"2026-06-04","ACTUAL",{"date":43,"type":41},"1997-04-21",{"name":45,"class":46},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":47},"100595922","phase-1-effects-of-inhaled-epinephrine-on-systemic-allergic-reactions-during-allergy-testing-immunotherapy-or-oral-challenges-100595922","NCT07038746","Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges","A Phase 1b, Open-Label, Exploratory Study Evaluating the Effects of Inhaled Epinephrine in Individuals Experiencing Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges","Inclusion Criteria:\n\n1. Males or females, aged ≥ 12 years with known or suspected allergen sensitivity who can also have a clinical history of immunoglobulin E (IgE)-mediated allergy, including a documented sensitivity to allergens (i.e., positive skin prick test, or positive in vitro serum IgE).\n2. Have undergone either a) allergy testing for suspected sensitivity\u002Fallergy, b) future oral challenge (food and\u002For drug) or future OIT to treat existing allergies or c) SCIT AND experienced a SAR Grade 2 or higher, following allergy testing, SCIT, or oral challenges (food and\u002For drug) for future OIT, and deemed eligible for enrollment by the Principal Investigator.\n3. For females of child-bearing potential, not pregnant or lactating, willing to use an acceptable contraception\\* method between Screening and End-of-Study Visits.\n\nExclusion Criteria:\n\n1. Known reaction or sensitivity to epinephrine or any of the ingredients of inhaled epinephrine.\n2. Known history or presence of clinically disease\u002Fcondition that could confound the results of the study or place the subject at undue or additional risk per the judgment of the Investigator.\n3. Abnormal vital signs at screening (i.e., systolic blood pressure: \\\u003C 90 or \\>140 mmHg, diastolic blood pressure: \\\u003C 40 or \\> 90 mmHg or, heart rate: \\\u003C 45 or \\> 100 bpm), respiration rate \\\u003C 8 or \\> 20 resp.\u002Fmin.\n4. Females who are pregnant, plan to become pregnant or lactating.\n5. Participation in another clinical study involving an investigational drug within 30 days prior to screening, an investigational biologic within 60 days prior to screening, or current\u002Fplanned participation in another interventional study during this study.\n6. Previous treatment in this study.\n7. Any other reason that, in the opinion of the Investigator, is likely to unfavorably alter subject risk-benefit, confound results, or make it difficult for the subject to fully comply with study requirements.","12 Years",{"count":57,"type":21},100,"INTERVENTIONAL",[60],"PHASE1","The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and\u002For drug) or oral immunotherapy (OIT).",[28,63],"Anaphylaxis",[65,66,67,68,28,69,63,70,71,72,73],"Immunotherapy","Epinephrine","Upper airway laryngeal edema","Upper airway pharyngeal edema","Hypersensitivity, immediate","Vasoconstrictor agents","Adrenergic alpha-Agonists","Adrenergic beta-Agonists","Bronchodilator agents","2026-02-03",{"date":76,"type":41},"2026-02-05",{"date":78,"type":41},"2025-08-25",{"date":80,"type":21},"2026-07",{"name":82,"class":83},"Dr. George Luciuk","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":93,"maxAge":55,"enrollmentInfo":94,"targetDuration":4,"studyType":58,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100620068","intraosseous-vs-infiltration-anesthesia-in-molar-incisor-hypomineralization-mih-children-100620068","NCT07352813","Intraosseous vs Infiltration Anesthesia in Molar-Incisor Hypomineralization (MIH) Children","A Comparative Evaluation of the Clinical Effectiveness of Computer-Assisted Intraosseous and Infiltration Anesthesia Techniques in Children With Molar-Incisor Hypomineralization","MIH","Inclusion Criteria:\n\n* Individuals applying to the Department of Pedodontics, Ankara Yıldırım Beyazıt University Faculty of Dentistry,\n* Systemically healthy individuals,\n* Individuals without any known allergies,\n* Children between the ages of 6 and 12 years,\n* Scoring 3-4 according to the Frankl Behavior Rating Scale,\n* Children and their legal guardians who, after reading and listening to the informed consent form, fully understand its content and voluntarily provide both verbal and written consent,\n* Children with contralateral and homologous maxillary first permanent molars affected by molar-incisor hypomineralization (MIH) and scoring 3-4 according to the MIH Treatment Need Index criteria,\n* Children with no emergency treatment needs, such as dental pain,\n* Both male and female volunteers.\n\nExclusion Criteria:\n\n\\-",true,"6 Years",{"count":95,"type":21},30,[97],"NA","This study aims to compare the effectiveness of intraosseous and infiltration anesthesia techniques administered using a computer-assisted anesthesia device (SleeperOne® 5; Dental HiTec, France) during restorative treatments of permanent first molars affected by Molar-Incisor Hypomineralization (MIH) in children. Clinical effectiveness will be evaluated based on the Visual Analogue Scale (VAS), behavioral pain response, pulse rate , salivary chromogranin A levels, and the need for additional anesthesia.",[100,28],"Molar Incisor Hypomineralization",[102,103,104,105],"caries","dental anxiety","dental pain","molar incisor hypomineralization","2026-01-13",{"date":108,"type":41},"2026-01-20",{"date":110,"type":41},"2025-11-07",{"date":112,"type":21},"2026-12-01",{"name":114,"class":83},"Ankara Yildirim Beyazıt University",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":58,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100617488","application-of-child-life-services-in-pediatric-skin-prick-test-100617488","NCT07319273","Application of Child Life Services in Pediatric Skin Prick Test","Inclusion Criteria:\n\n* Meet the indications for skin prick test (SPT)\n* Aged 1-18 years\n* Voluntarily agree to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Meet the contraindications for SPT\n* Presence of psychiatric disorders or cognitive impairment\n* Severe dysfunction of vital organs such as the heart, brain, or kidneys","18 Years",{"count":123,"type":21},140,[97],"The goal of this clinical trial is to determine whether child life services can enhance the experiences of children and caregivers during skin prick testing. The main questions it aims to answer are:\n\n1. Can child life services alleviate children's pain and enhance procedural compliance?\n2. Can child life services reduce caregivers' anxiety and improve their satisfaction? Researchers will compare children who receive child life services with those who receive standard care to determine whether the intervention can optimize procedural experience and overall satisfaction.\n\nParticipants will receive either child life services or standard care during the skin prick test.",[28,127],"Pediatrics",[129,130,131,132,133],"child life services","skin prick test","pain","anxiety","pediatric nursing","NOT_YET_RECRUITING","2025-12-21",{"date":137,"type":41},"2026-01-06",{"date":139,"type":21},"2026-01",{"date":141,"type":21},"2026-12",{"name":143,"class":83},"Children's Hospital of Fudan University",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":92,"sex":16,"minAge":152,"maxAge":121,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100247201","pediatric-arm-of-dzl-all-age-asthma-cohort-100247201","NCT02496468","Pediatric Arm of DZL All Age Asthma Cohort","The All Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL), Pediatric Arm","ALLIANCE","Inclusion Criteria:\n\n* informed consent by parents (and by children if age \\> 8 years)\n* age 6 months to 18 years\n* term delivery (≥ 37 weeks)\n* active\u002Fpassive understanding of German\n* age 6 months - \\\u003C 6 years: preschool wheeze (more than two episodes of wheeze during 12 months prior to inclusion)\n* age at least 6 years: doctor diagnosed asthma (according to current guidelines)\n\nExclusion Criteria:\n\n* known inborn or perinatal pulmonary disease\n* airway malformation\n* oxygen therapy after birth with a duration of more than 24 hours\n* ventilator support or mechanical ventilation after birth\n* diagnoses of cystic fibrosis; primary ciliary dyskinesia\n* heart failure diagnosed after birth affecting pulmonary circulation\n* major respiratory diseases such as e.g. interstitial lung disease\n* any current non-atopic comorbidity\n* fever of at least 38.5°C during the last two weeks prior to the planned first visit","6 Months",{"count":154,"type":21},1500,"Despite its common occurrence, still little is known about pathomechanisms determining different wheeze and asthma trajectories and phenotypes in children, and those beginning in adulthood. Therefore, deciphering underlying determinants for different childhood and adult asthma phenotypes is urgently needed to develop personalized treatment approaches targeting distinct underlying mechanisms. Thereby, secondary prevention early in the disease process can also be achieved. The decoding of such mechanisms and their translation to the individual patient is the aim of the Disease Area Asthma Allergy of the 'German Centre for Lung Research' (DZL).",[35,157,28,158],"Wheeze","Endophenotype",[160,161,162,163,164,165,166],"childhood asthma","preschool wheeze","adult asthma","transition","phenotype","endotype","trajectory","2024-08-27",{"date":169,"type":41},"2024-08-28",{"date":171,"type":4},"2013-01",{"date":173,"type":21},"2027-12",{"name":175,"class":83},"LMU Klinikum",5,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":92,"sex":16,"minAge":121,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":58,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":134,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":4},"100557439","assessment-of-eryag-laser-for-the-control-of-hypersensitivity-during-tooth-whitening-with-hydrogen-peroxide-100557439","NCT06538129","Assessment of Er:YAG Laser for the Control of Hypersensitivity During Tooth Whitening With Hydrogen Peroxide","Assessment of Er:YAG Laser for the Control of Hypersensitivity During Tooth Whitening With Hydrogen Peroxide: Protocol for a Split-Mouth Controlled Clinical Trial","Inclusion Criteria:\n\n* All anterior teeth present without caries or restorations;\n* Absence of cervical lesions, dental pain and hypersensitivity prior to treatment;\n* Not having previously undergone any tooth whitening procedure.\n\nExclusion Criteria:\n\n* Smokers;\n* Pregnant or nursing women;\n* Individuals with gingivitis or periodontitis, those with enamel cracks detected by the transillumination test;\n* Those with enamel defects or stains caused by tetracycline;\n* Those with systemic diseases;\n* Those taking nonsteroidal anti-inflammatory.","45 Years",{"count":186,"type":21},28,[97],"Introduction: Tooth whitening is an aesthetic procedure with rapid results that improves the self-esteem and self-image of patients. However, one of the side effects is dentinal hypersensitivity. The aim of the study is to assess the effectiveness of Er:YAG laser administered prior to bleaching with 35% hydrogen peroxide hypersensitivity.\n\nMethods: The maxillary arch of participants 18 to 45 years of age will be treated using the split-mouth method. Grupo experimental: Hypersensitivity prevention protocol with Er:YAG laser followed by bleaching with 35% hydrogen peroxide; control group: hypersensitivity prevention protocol with neutral sodium fluoride for four minutes followed by bleaching with 35% hydrogen peroxide. Er:YAG laser (2940 nm) will be used with the following parameters: 0.15 W, 10 mJ, 15 Hz and SP mode (pulse duration: 300 µs), TIP: Cylindrical Quartz 1000\u002F4, using the H14 handpiece (H14 for LightWalker AT; Fotona dd, Ljubljana, Slovenia). Each tooth (central incisor, lateral incisor and canine) will be irradiated twice for 10 s in an unfocused scanning motion in the cervical region at a working distance of 1 cm. The absolute risk and intensity of dentinal hypersensitivity during treatment will be assessed using the visual analogue scale. The change in color will be determined using an intraoral spectrophotometer in contact with the tooth. Assessments will be conducted before and after preventive treatment, immediately after treatment as well as 48 hours and one week after treatment. Different statistical tests will be used, with the significance level set at 5% (p ≤ 0.05).",[28,190,191],"Hypersensitivity, Immediate","Hypersensitivity Response","2024-07-31",{"date":194,"type":41},"2024-08-05",{"date":196,"type":21},"2024-11-01",{"date":198,"type":21},"2026-09-01",{"name":200,"class":83},"University of Nove de Julho",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":92,"sex":16,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":58,"phases":212,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":47},"100551734","a-clinical-trial-to-compare-lasotronix-alone-or-in-combination-with-cpp-acp-to-treat-dh-100551734","NCT06463938","A Clinical Trial to Compare Lasotronix Alone or in Combination With CPP-ACP to Treat DH","A Clinical Study to Evaluate the Effectiveness of Casein Phosphopeptide, Amorphous Calcium Phosphate Paste (CPP-ACP) Used Alone or in Combination With Lasotronix (Diode Laser) to Treat Dentin Hypersensitivity","Inclusion criteria:\n\n* Patients of either gender, with ages between 25-65 years\n* should have at least more than one hypersensitive and vital tooth without any carious lesion or defective restoration\n\nExclusion criteria:\n\n* History of desensitizing therapy on the affected tooth\u002Fteeth in last six months (use of desensitizing toothpaste)\n* use of antibiotics \u002Fanalgesic\u002Fanti-inflammatory drugs\n* history of smoking\n* pregnancy\n* those who are not willing to participate or give follow-ups","25 Years","65 Years",{"count":211,"type":21},120,[97],"Dentin hypersensitivity (DH) is defined as sharp pain of a shorter duration arise from exposed dentin in response to several chemicals and thermal or tactile stimuli that cannot be ascribed to other dental defects\". DH has a prevalence rate ranging from 1.3% to 92.1%, commonly affecting old ages. The use of laser has opened new dimensions in the treatment of DH. To the author's knowledge, not much research work has been conducted using LASOTRONIX as a treatment modality with CPP-ACP. Therefore, this research aims to determine the effectiveness of Casein phospho peptide paste (CPP-ACP) used alone or combined with a diode laser (LASOTRONIX).",[215,28,216],"Dentin Sensitivity","Cervical Lesion",[215,218,219],"Lasotronix","Diode laser","2024-07-25",{"date":222,"type":41},"2024-07-26",{"date":224,"type":41},"2024-05-12",{"date":226,"type":21},"2024-10-10",{"name":228,"class":83},"Dow University of Health Sciences"]